Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Another PR slant on validation:
http://www.stockhouse.com/news/news.asp?tick=DNAG&newsid=4853114
Ann
Listen to the archived events audio:
http://biz.yahoo.com/cc/5/75735.html
Ann
Posted by: frogdreaming
In reply to: frogdreaming who wrote msg# 53173 Date:12/20/2006 9:48:25 PM
Post #of 53233
"Au contraire, my silly friend."
(The self-proclaimed Frog caught talking to himself) - lol
Anonymous,
Ann
Sandoz:
Really appreciate your comment!
Take care,
Ann
Here it is:
(took a drum roll - lol)
http://www.icq.com/friendship/pages/browse_page_7944.html
Ann
Might as well get in the "spirit" now - this is my annual Xmas greeting to all of the DNAPers:
Same ole Fru Fru:
One example of why I posted one of the releases:
"Next-to-Last Step for Testing Company's Anemia Drug Prior to Pre-IND Meeting With FDA"
The above was not noted in the release that we read on the day it was issued. From my perspective, it is an interesting point to note that we are that far along in our testing. You have the choice not to read my posts, however, if you feel I'm in such a psychological disadvantage as not to know what is relevant or not. And, please, just try not to 'tongue in cheek' humor me along!
Take care,
Ann
Sorry:
Here is the release:
http://biz.yahoo.com/iw/061016/0170559.html
Ann
Next to last step for PT, prior to meeting w/FDA:
A read on DNAP's Ethniticy test:
http://www.drugresearcher.com/news/printNewsBis.asp?id=54499
Ann
Correction in Aug. Press release re: DNAP:
http://www.marketwire.com/mw/release_html_b1?release_id=156727&tsource=3
Ann
And this:
DNAPrint Genomics Appoints Two Scientists to Key Positions
at Computational Biology Division
SARASOTA, FL--May 18, 2006 -- DNAPrint Genomics, Inc. (OTC BB:DNAG.OB - News) today announced the appointment of two experienced scientists to key positions in the Computational Biology Division of DNAPrint Pharmaceuticals, Inc., the Company's wholly owned subsidiary.
Tandy Herren, Ph.D., was named Director of Simulation Technology and Neil Kabrun, Ph.D., Director of Biological Modeling. Dr. Herren will be responsible for applying DNAPrint's proprietary BioFusion(TM) simulation technology, as well as other modeling techniques to support the Company's drug and diagnostics product development programs. Dr. Kabrun is responsible for the acquisition and implementation of a toolbox of techniques and systems that will continue to advance the role of computational methods in improving product development.
Dr. Herren, formerly a scientist at Kenna Technologies, (acquired by DNAPrint Genomics in November 2005) was a co-founder and a co-inventor of the simulation methods currently utilized by DNAPrint Pharmaceuticals. Dr. Kabrun served as an independent consultant before joining DNAPrint Pharmaceuticals.
"DNAPrint Pharmaceuticals has already benefited from the impact of simulation technology in the development stage of the Company's first drug, PT-401, an enhanced form of the blood 'booster drug' erythropoietin," stated Barbara Handelin, Ph.D., DNAPrint General Manager of Computational Biology. "The team of Herren and Kabrun developed a simulation model for PT-401 that provides key insights into PT-401's performance characteristics, including its benefits over conventional forms of erythropoietin. Their work is crucial to our research leading to preclinical studies of PT-401."
"DNAPrint Pharmaceuticals is pleased to have attracted two experienced scientists in this important new field of computational biology," stated Hector J. Gomez, M.D., Ph.D., Chairman and Chief Medical Officer of DNAPrint Genomics, Inc. and head of the DNAPrint Pharmaceuticals subsidiary. "We are committed to the value that computational biology brings to our drug and diagnostic development programs."
Thumbs up!
Ann
Altar:
Just keep klickin' your beads!
A nice weekend to you,
Ann
Sam:
"Good Show!"
Ann
Geob:
"We're gonna be rich $$$$"
Pleeze, Try to contain yourself! - lol
Ann
About NYSSA & you can also surf their website:
http://www.nyssa.org/Content/NavigationMenu/about_nyssa/history___mission/history___mission.htm
Ann
Dr. Fru:
"If you prefer not to respond, I shall understand and not take offense."
But, you might take offense, if I DO respond! - lol
There are others here that are much more willing to induce a serious conversation with you re: our investment and at times may want to smack your snake lips.
But, you take care...
Ann
Ok, Geob...we've read this story again and again, got the message...
Take a breath, Geob...do some Xmas shopping while there's time - lol
Ann
Derrick Lee Todd mentioned in today's news article:
Updated:2006-12-02
Arrest Made in Louisiana Serial-Killer Probe
HOUMA, La. (Dec. 2) - A multi-agency task force investigating the strangling and asphyxiation deaths of as many as 22 men arrested a 42-year-old Terrebonne Parish man at a homeless shelter on Friday and booked him with two of the earliest ones.
"Scientific, forensic evidence" led to the arrest of Ronald J. Dominique, who was booked with killing Oliver Lebanks in October 1998 and Manuel Reed in May 1999, and with raping Reed, state Attorney General Charles Foti's office announced. He had been under 24-hour surveillance before the arrest, spokeswoman Jennifer Cluck said.
Both Reed, 20, of New Orleans, and Lebanks, 27, were killed in Jefferson Parish, a suburb of New Orleans about 45 miles east of Houma, according to a news release. Reed's body was found in Kenner and Lebanks' in Metairie. Cluck said they did not have information on Lebanks' hometown.
Dominique was arrested on charges of first-degree murder and aggravated rape in Reed's death, and with the second-degree murder of Lebanks, who died of asphyxiation, said Kris Wartelle, another spokeswoman for Foti.
"Due to the fact that the investigation is ongoing and there is a possibility of more charges, no further information is available at this time," the news release said.
There will be "more information to come in the very near future," Les Bonano, an investigator with the attorney general's office, said at the news conference.
Reed's body was found in a business garbage bin May 30, 1999. Kenner police said last year that they believed his death was linked to the killings of two men from the St. Charles Parish town of Boutte, about halfway between Houma and New Orleans. The body of Joseph Brown, 16, was found in October 1998 at the western end of Veterans Memorial Boulevard; that of Angel Mejia, 21, was found next to a garbage bin one month after Reed's.
Brown had been suffocated; Mejia and Reed were strangled, authorities said.
Kenner police had dubbed the three killings "the shoeless murders," and believed they could have been linked to other murders in the region.
Although the news release said Dominique was from Houma, the address it gave is actually about 5 miles out of town on the Terrebonne-Lafourche parish line.
The task force had been investigating the deaths of men, mostly between the ages of 18 and 40, for more than a year. The first killing was in 1997. The victims were found in Jefferson, St. Charles, Lafourche, Terrebonne, Assumption and Iberville parishes.
Many of the men were poor; some were willing to prostitute themselves for drugs. They had been strangled without the bruises or broken bones that would indicate a struggle.
Houma Police Chief Patrick Boudreaux was one of the first to investigate them as serial killings. The killings weren't like the usual drug killing, with a victim shot and left to die.
Three victims were found in the same sugar cane field. Some were missing their shoes.
Until Friday, many authorities - including Foti - shied away from saying southeastern Louisiana had its third serial killer investigation in a matter of years.
There had been no DNA evidence, like that which led to the conviction of Derrick Todd Lee and the arrest and reported confessions of Sean Vincent Gillis in the two earlier cases.
Nine of the unsolved cases were from the late 1990s. The others, since 2000, included many victims with ties to the Houma area.
Because most of the victims led what authorities termed "high-risk" lifestyles, the killings caused less public unrest than those of the college and professional women whom Lee was accused of killing between April 1998 and March 2003. He was sentenced to death for first-degree murder of a former Louisiana State University student in Baton Rouge, and sentenced to life for second-degree murder of a West Baton Rouge woman in 2002. Authorities said DNA had linked him to the deaths of five other women.
Prosecutors have said that Gillis confessed to killing eight women. He has been booked in seven of the cases, and charged with first-degree murder of one, Donna Bennett Johnston. Her body was found by a roadside on Feb. 27, 2004. Gillis was arrested about two months later. Authorities have said DNA and tire tracks linked him to the crime.
Ann
Bag:
"From frudIago, to frog, to fraudalent posts"
Like being at the race track again - lol
I wish the same to you this Holiday Season!
Ann
Bag:
Are we having fun yet? - lol
Take care,
Ann
Is anyone having trouble with their last postings not holding to being highlighted after read?
If I'm the only one experiencing this, then ok. However, if not, it's at the point where IHUB needs to correct this issue.
Ann
Biogrontera & DNAP trading:
http://www.marketwire.com/mw/release_html_b1?release_id=179091
Ann
DNAP sells kits and receives positive feedbacks:
http://www.marketwire.com/mw/release_html_b1?release_id=182761
Ann
DNAP's funding of Federal Sources:
http://www.stockhouse.com/news/news.asp?tick=DNAG&newsid=4795900
Ann
Biofrontra's business partner:
http://www.marketwire.com/mw/release_html_b1?release_id=186878
Ann
And how about this Notice of Allowance of Patent?
http://biz.yahoo.com/iw/060420/0123973.html
Ann
DNAP's Computational Biology Division:
http://www.macreport.net/todaysMarkets.asp?id=2789
Ann
On Statinome:
"STATINOME™ - This test is currently being developed for the cardiac drug market, and is expected to enable a classification of patients as adverse responders or normal responders to a class of drugs known as “statins”. Statins are drugs used to treat patients who are at increased risk of heart disease. Once perfected, we believe STATINOME™ should be able to improve the rewards associated with taking statins by reducing the risks associated with adverse response sometimes seen in minority of patients.
In addition to OVANOME™, we have initiated several studies for cancer drugs with the H. Lee Moffitt Cancer Research Center in Tampa, FL (colon cancer, post-operative nausea and vomiting in cancer patients undergoing surgery and multiple Myeloma). We hope to develop the additional expertise to help us better guide the clinical development of compounds that we will be acquiring for our own drug development pipeline."
Good luck to all!
Ann
On Ovanome from E-Symposium:
"Our scientists have identified several Single Nucleotide Polymorphism (“SNP”) markers whose haploid alleles are predictive for non-response to the Taxol and Carboplatin drug combination.
The next step for OVANOME™ is to be tested in prospective clinical trials. These trials will give the final validation and determine the clinical usefulness of the predictive test. . Our Chief Medical Officer, Hector J. Gomez, MD, PhD will lead the clinical development process.
FDA rules regarding pharmacogenomics testing are still evolving and everyone in the industry is seeking additional guidance from the FDA on this issue. Until OVANOME™ is FDA approved or deemed to not require FDA approval, we plan on generating revenues by developing and testing OVANOME and similar tests for other drugs through physician guided Investigative New Drug studies. Recently, we announced that we have begun a formal evaluation of patient’s and patient samples in conjunction with the Moffitt Cancer Center and associated Groups of specialists."
Ann
'05 - DNAP aspirations, an interesting read:
http://www.tampabay.org/press.asp?rls_id=933&cat_id=22&
Ann
Iwant:
I would almost rather see Jever00 post again, than Jever000(Geob). - Either way, it isn't really that important. - lol
Take care,
Ann
Jeever's this story been out sooner than you posted it...calm down!
Ann
Geob:
Just calm down!
Ann
Dru to Bag:
"I do hope it not be presumptuous of me to respond to your post inasmuch as my bastardized alias was irreverently referenced by you in your message to our eternally optimistic ann."
Watch your language,Daky!...and it's St. Ann, to you (if you insist in using my name in vain) - lol
Ann
Bag:
Like to think positive - we do have a choice, you know - lol
Take care,
Ann
Same heading as PR of 11/14, posted on 11/16:
http://money.aol.com/news/articles/_a/dnaprint-genomics-recommends-federal/n20061116175209990015
Ann
From the second posting of the last PR:
"In 2005, the National Institute of Justice (NIJ) provided $14 million in funding to 38 States and units of local government to search, evaluate, select, and conduct DNA analysis on violent crime "cold cases" that have the potential to be solved through DNA testing, according to federal government sources.
NIJ also provides funding to support regional training opportunities for "cold case" investigators from law enforcement agencies nationwide. These training events are being delivered by NIJ through its cooperative agreement with the National Forensic Technology Center, a member of the NIJ Forensic Resource Network, according to federal government sources.
Ann
Work:
Ellipsis Biotherapeutics is a wholly owned subsidiary of DNAPrint™ genomics . DNAPrint specializes in Forensic Science, Genealogical Research, and Pharmaceutical development. Ellipsis Biotherapeutics, formerly privately held, has retained its name and functions as a Canadian company from its corporate headquarters in Toronto, Ontario. Ellipsis has retained its existing personnel and continues to be managed by Dr. Laurence Rubin
Trace Genetics (www.tracegenetics.com)
Trace Genetics, based in Richmond, California, is another wholly owned subsidiary of DNAPrint™ genomics. Trace Genetics is a full service DNA laboratory, with expertise in Gene Genealogy, Forensics, Molecular Diagnostics and Population Genetics.
Ann